ADVERTISEMENT
CD19 Biological Pathways Reviews
CD19
B-lymphocyte antigen CD19; CD19 molecule; B-Lymphocyte Surface Antigen B4; T-Cell Surface Antigen Leu-12; CVID3
CD19 antigen is a type I transmembrane glycoprotein that is expressed in normal and malignant B cells.1 It plays a role in B cell development and maturation by modulating B-cell receptor signaling during lymphopoiesis.2,3 CD19 deficiency leads to an impaired humoral response, resulting in increased susceptibility to infection.1
Understanding the Role of CD19
This animation explains the role of the CD19 antigen in the primary signaling complex on the surface of B-cells and the effect of overexpression of this antigen.
Expression in Cancer
CD19 Targeting Therapies
Therapies targeting CD19 dysrupt MYC signaling and interfere with oncogenesis. There are multiple drug classes designed to target CD19. This table outlines therapies targeting CD19 both approved by the FDA and in the pipeline.
|
CD19 Targeting Therapies Approved by the FDA |
|
|
Brand Name (Generic Drug Name) |
Indications |
|
Monjuvi (tafasitamab)1 |
Treatment in combination with lenalidomide for adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant |
|
Blincyto (blinatumomab)2 |
Treatment of adults and children with CD19-positive B-cell precursor ALL in first or second complete remission with MRD ≥0.1% |
|
Treatment of adults and children with relapsed or refractory CD19-positive B-cell precursor ALL |
|
|
Kymriah (tisagenlecleucel)3 |
Treatment of patients up to 25 years with B-cell precursor ALL that is refractory or in second or later relapse |
|
Treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after 2 or more lines of systemic therapy, including DLBCL not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma |
|
|
Treatment of adult patients with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy |
|
|
Yescarta (axicabtagene ciloleucel)4 |
Treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy |
|
Treatment of adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma |
|
|
Treatment of adult patients with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy |
|
|
Breyanzi (lisocabtagene maraleucel)5 |
Treatment of adult patients with large B-cell lymphoma, including DLBCL not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy |
|
Treatment of adult patients with large B-cell lymphoma, including DLBCL not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who have refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation due to comorbidities or age |
|
|
Treatment of adult patients with large B-cell lymphoma, including DLBCL not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who have relapsed or refractory disease after two or more lines of systemic therapy |
|
|
CD19 Targeting Therapies in the Pipeline |
|
|
Loncastuximab tesirine6 |
Treatment being evaluated in B-cell malignancies and Waldenström macroglobulinemia |
|
TNB-4867 |
Treatment being evaluated in relapsed or refractory B-cell non-Hodgkin lymphoma |
